STOCKS TELEGRAPH

Category: US Stocks

  • After-Market Momentum Builds For SkyWater (SKYT) After Announcing Robust Q2 Results

    After-Market Momentum Builds For SkyWater (SKYT) After Announcing Robust Q2 Results

    During the after-hours trading session, SkyWater Technology, Inc.’s (NASDAQ: SKYT) share price had a significant boost, jumping 22.44% to $10.86. The rise came after the completion of a major strategic acquisition—Infineon’s U.S.-based semiconductor manufacturing plant, Fab 25 in Austin, Texas—and the announcement of second-quarter financial results that exceeded projections.

    The Acquisition Of Fab 25 Will Result In Significant Revenue Growth.

    SkyWater has achieved a significant milestone with the acquisition of Fab 25, which is fully financed by a flexible senior secured revolving credit facility that may borrow up to $350 million. Beginning in Q3, SkyWater anticipates that Fab 25 will be accretive to both adjusted EBITDA and free cash flow, and it will generate at least $300 million in sales annually.

    With $73 million in cash and an extra $20 million for working capital, the total transaction price came to about $93 million. This is an updated transaction structure that increases the upfront payment by $18 million and eliminates a $25 million payment linked to a supply agreement.

    Strategic Supply Agreement and US Semiconductor Push

    With an estimated multi-year supply agreement valued at more than $1 billion, Fab 25 offers the scalability and process flexibility required to meet the core needs of the semiconductor industry. In addition to supporting national objectives for safe, onshore semiconductor manufacturing, this enhances SkyWater’s standing in America’s industrial and technological resilience.

    Extension of Quantum Computing and Advanced Packaging

    Beyond Fab 25, SkyWater is advancing in innovative areas such as quantum computing and advanced packaging. In order to create next-generation quantum systems, SKYT is honing its expertise in two fields: chiplet integration and superconducting films.

    It is also enhancing infrastructure at its Kissimmee, Florida factory, which is nearing a significant installation of new machinery to support its Advanced Packaging platform, in anticipation of a projected revenue ramp in the second half of 2025. With its expanding capabilities and commitment to semiconductor innovation in the US, SkyWater is well-positioned for substantial growth in 2026 as a result of all of these initiatives.

  • Astera Labs (ALAB) Stock Advances After-Hours On Strong Q2

    Astera Labs (ALAB) Stock Advances After-Hours On Strong Q2

    After strong second-quarter earnings, shares of Astera Labs, Inc. (NASDAQ: ALAB) saw significant movement in extended trading. After hours, ALAB’s shares rose 17.31% to settle at $159.00. The business reported a 20% sequential increase in revenue, which significantly improved profitability and operating cash flow.

    Growth in Revenue and Key Financial Data

    Astera Labs made $191.9 million in Q2, which was a 150% increase year over year and a 20% sequential increase. At 75.8%, the gross margin remained robust. $51.2 million was the quarter’s net income, which translates to $0.29 diluted profits per share.

    This success was driven by several new design wins for its Scorpio Fabric Switches and the expansion of its PCIe 6 product range into volume manufacturing for bespoke rack-scale AI systems.

    Product Expansion and Market Demand

    Astera Labs experienced sustained demand for its signal conditioning portfolio, driven by PCIe scale-up and Ethernet scale-out applications in custom ASIC platforms. The firm, which is leading the way in the transformation of AI infrastructure, is increasing expenditures in order to realize its goal of rack-scale connection for AI systems of the future.

    Strategic Partnerships and the Development of Ecosystems

    Astera Labs and NVIDIA deepened their partnership during the quarter to develop the NVLink Fusion ecosystem, which will allow hyperscalers to set up high-performance scale-up networks. The company’s NVLink connectivity solutions integrate seamlessly with its Intelligent Connectivity Platform, which incorporates PCIe, CXL, and Ethernet solutions, alongside the COSMOS software suite for optimized data center performance.

    Astera Labs also hosted a comprehensive Ultra Accelerator Link (UALink) webinar, underscoring its role as a Promoter Member of the UALink Consortium. UALink is the only open standard tailored for scale-up applications, designed to deliver high bandwidth, low latency, and broad interoperability.

    Collaborations to Promote AI Infrastructure

    Astera Labs demonstrated its industry presence by attending AMD’s Advancing AI 2025 event as a reliable partner and highlighting the crucial role that UALink plays in next-generation AI architectures. Furthermore, a collaboration with Alchip Technologies was revealed to combine Astera Labs’ connectivity solutions with Alchip’s specialized ASIC capabilities, providing verified, compatible products for hyperscalers developing cutting-edge AI infrastructure.

  • 4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data

    4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data

    In the most recent session, shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have had a notable surge, rising 14.89% to trade at $5.17. The biotechnology company saw a surge with the release of positive results from ongoing clinical trials and the confirmation of regulatory alignment with the European Medicines Agency (EMA) for its lead candidate 4D-150 in diabetic macular edema (DME).

    Encouraging Data from SPECTRA Phase 2a Trial

    Positive interim findings from the SPECTRA clinical study, which assesses the safety and effectiveness of intravitreal 4D-150 in adult DME patients, were released by 4D Molecular. At the 43rd Annual American Society of Retina Specialists (ASRS) Scientific Meeting, Dr. David Almeida of Erie Retina Research gave an oral presentation of data from the 52-week main endpoint and 60-week analyses.

    In comparison to the standard-of-care aflibercept 2 mg given every eight weeks, the results showed that 4D-150 had great tolerability and consistent, long-lasting clinical action, indicating its potential as a backbone therapy that might significantly lower treatment frequency.

    Regulatory Alignment and Streamlined Development Path

    In addition to the positive clinical readout, the company confirmed alignment with EMA on a registrational pathway for 4D-150 in DME. Both regulatory agencies have consented to a single Phase 3 study after reaching a similar arrangement with the U.S. Food and Drug Administration (FDA) earlier this year.

    Existing data from PRISM, SPECTRA, and the 4FRONT wet age-related macular degeneration (wet AMD) program will support that, and it would be adequate for a DME marketing permission application. A clearer development trajectory is provided by this simplified method, which may hasten patients’ access to the treatment.

    Possibility of Revolutionizing the Treatment of Retinal Disease

    4D-150’s potential to become a cornerstone treatment for retinal vascular disorders is highlighted by its consistent effectiveness, dosage response, and safety profile across both DME and wet AMD studies. 4D-150 has the potential to drastically lower the treatment burden by providing long-lasting vision benefits with fewer treatments. This is especially important for the working-age population, which is frequently impacted by DME.

    4D Molecular now has a clear regulatory road to provide its novel medication to patients with two of the most common blinding retinal disorders thanks to unified advice from the FDA and EMA.

  • Chart Industries (GTLS) Stock Surges In After-Market Trading

    Chart Industries (GTLS) Stock Surges In After-Market Trading

    Following news of a possible takeover deal, Chart Industries, Inc.’s (NYSE: GTLS) stock saw a sharp increase on Monday. After-hours trading saw GTLS shares rise 18.28% to $203.02.

    According to the Financial Times, the rise coincides with Baker Hughes, a major player in the oil and gas equipment industry, apparently nearing completion of a $13.6 billion cash agreement to buy Chart Industries. However, the deal is still being negotiated and is not yet complete, the magazine stated.

    Baker Hughes Edges Out Rival Bid

    Baker Hughes’ reportedly proposed deal surpasses a previous $19 billion all-stock merger agreement between Chart Industries and Flowserve, which was announced in June but has since been terminated. The proposal from Baker Hughes caused Chart’s board to reevaluate its previous commitment to Flowserve by providing an equity valuation of $210 per share, which was 22% more than Chart’s market price.

    The purchase is in line with Baker Hughes’ overarching plan to increase its presence in the LNG and natural gas markets by diversifying its portfolio of energy and industrial technologies.

    Part of a Larger Energy Sector Consolidation

    The possible takeover comes amid an ongoing wave of consolidation in the U.S. energy industry. In 2023 alone, mergers and acquisitions in the sector reached $250 billion, although activity slowed toward the end of the year.

    As of Monday’s close, Chart Industries maintained a market capitalization of $7.71 billion. The company is recognized for manufacturing advanced industrial equipment, including valves and measurement systems for handling gas and liquid molecules.

    LNG Alliance Selects Chart’s IPSMR Technology

    In a separate development this month, Chart Industries secured a significant contract with LNG Alliance Pte Ltd for its Amigo LNG export facility in Guaymas, Sonora, Mexico. With a 7.8 million tonnes per annum (MTPA) capacity, the plant will use Chart’s modular liquefaction system and IPSMR (Integrated Pre-cooled Single Mixed Refrigerant) process technology.

    By enabling operators to customize liquefaction systems to site-specific conditions, this technique aims to maximize efficiency by guaranteeing the optimal ratio of cold box capacity to compression power. It is anticipated that this capacity would reduce expenses for LNG Alliance while improving operational performance.

  • Celcuity (CELC) Stock Surges After Announcing Landmark Trial Success

    Celcuity (CELC) Stock Surges After Announcing Landmark Trial Success

    Following the announcement of noteworthy clinical trial advancements, Celcuity Inc. (NASDAQ: CELC) stock saw a surge in value. The CELC stock was trading at $38.31 as of the most recent check, representing a remarkable 178.18% increase. The company’s Phase 3 VIKTORIA-1 trial’s PIK3CA wild-type group showed encouraging topline findings.

    After advancement on a CDK4/6 inhibitor and an aromatase inhibitor, the research compared gedatolisib with fulvestrant—with or without palbociclib—against fulvestrant in patients with hormone receptor (HR)-positive, HER2-negative, PIK3CA wild-type, locally advanced, or metastatic breast cancer.

    Revolutionary Progression-Free Survival Results

    In comparison to fulvestrant, the gedatolisib triplet showed a 76% decrease in the probability of disease progression or death, resulting in a statistically significant and clinically relevant increase in progression-free survival (PFS) (HR 0.24, 95% CI).

    According to the blinded independent central review (BICR), the median PFS was 9.3 months as opposed to 2.0 months with fulvestrant, representing a 7.3-month incremental improvement. With a 67% risk reduction and a 5.4-month advantage in mPFS from 2.0 months to 7.4 months, the gedatolisib doublet demonstrated comparable remarkable outcomes.

    Significant Advances in the Treatment of Advanced Breast Cancer

    For patients with HR+/HER2-advanced breast cancer receiving at least a second-line treatment, these results represent the highest favorable hazard ratios and PFS improvements yet documented in Phase 3 studies.

    Following CDK4/6 inhibitor advancement, gedatolisib becomes the first PI3K/AKT/mTOR pathway inhibitor to provide favorable Phase 3 results in HR+/HER2-/PIK3CA wild-type patients. Notably, both gedatolisib regimens showed better tolerability, fewer cases of stomatitis and hyperglycemia, and lower treatment dropout rates than observed in previous studies.

    Regulatory Route and Prospects

    The findings offer gedatolisib as a potentially revolutionary alternative for patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer. In Q4 2025, Celcuity intends to file a New Drug Application with the US Food and Drug Administration.

    By the end of 2025, topline findings for the VIKTORIA-1 PIK3CA mutation cohort are also expected. The trial’s significant PFS improvement points to a paradigm shift in the treatment strategy for this difficult patient group.

  • OFA Group (OFAL) Marks Progress With Digital Treasury News

    OFA Group (OFAL) Marks Progress With Digital Treasury News

    As of the most recent check, OFA Group, Inc. (NASDAQ: OFAL) saw a notable market response, with its shares rising 23.41% to $2.13. The company’s introduction of a digital asset treasury plan to improve its financial processes was followed by a spike in the stock price.

    The announcement was made in conjunction with OFA Group’s ceremonial ringing of the Nasdaq closing bell to mark the company’s IPO from the previous quarter and to acknowledge recent advancements in creating an ecosystem driven by innovation and high profitability.

    Integrating Digital Assets Strategically

    Through the creation of a digital asset treasury, OFA Group formally updated its shareholders on its intention to incorporate cryptocurrency holdings into its balance sheet.

    The company’s overarching plan to diversify its treasury holdings and use cutting-edge technologies to boost liquidity and capital efficiency is in line with this progressive financial initiative. By doing this, OFA hopes to strengthen its financial stability and create new sources of non-dilutive capital for strategic and operational needs.

    Flexibility in Finances and Professional Management

    Bitwise Asset Management will monitor the purchase of cryptocurrency assets, generate yield responsibly, and provide wider diversification as the manager of the digital treasury. 

    This move reflects OFA Group’s intent to generate sustainable returns from digital holdings while retaining operational flexibility.

    The strategy is expected to fund initiatives such as the expansion of its PlanAid platform, which automates building code compliance, and the launch of a new blueprint-generation tool for mechanical, electrical, and plumbing systems based on architectural layouts.

    Driving Innovation Through AI and Architecture

    Using proprietary AI technologies in architectural processes to speed up development, lower project costs, and increase returns is part of OFA Group’s innovation strategy. The company is also expanding its position in the design and development of senior living facilities, where artificial intelligence (AI) technology will be used to enhance overall experience, safety, and efficiency.

    Ready for the Financial Future

    The establishment of a digital asset treasury places OFA Group at the forefront of financial innovation and demonstrates the company’s methodical approach to capital management. The OFA Group is still working to fulfill its objective of providing innovative architectural solutions driven by revolutionary AI technology by fusing traditional finance with digital asset strategies.

  • Lifezone Metals (LZM) Gains In Pre-Market Amid Major Ownership Shift

    Lifezone Metals (LZM) Gains In Pre-Market Amid Major Ownership Shift

    Investor sentiment surged in the pre-market session as shares of Lifezone Metals Limited (NYSE: LZM) rose over 10%, reaching $4.90 as of the latest check. This sharp upward movement follows a strategic acquisition that positions the company at the forefront of a major nickel development.

    Lifezone has finalized a definitive agreement with BHP Billiton (UK) DDS Limited to acquire BHP’s 17% equity stake in Kabanga Nickel Limited (KNL), thereby assuming full ownership of KNL.

    Enhanced Ownership Structure and Offtake Control

    With this acquisition, Lifezone Metals now owns 100% of KNL, which in turn holds an 84% interest in Tembo Nickel Corporation Limited (TNCL), the operating entity for the Kabanga Nickel Project in northwestern Tanzania. The Government of Tanzania retains the remaining 16% in TNCL.

    The agreement also terminates all prior contractual arrangements with BHP, including the T2 Option Agreement. Lifezone now controls 100% of the project’s offtake, aligning commercial, technical, and ESG interests under a unified management structure.

    Transaction Terms and Deferred Payments

    Key terms include an initial fixed cash payment of $10 million, due within 30 days of either: (i) 12 months post-Final Investment Decision (FID) or (ii) after Lifezone secures $250 million in cumulative funding. An additional deferred payment will be made 12 months following first commercial production, indexed to Lifezone’s share price performance.

    This second payment ranges up to $83 million, with a reduction to $75 million if a Resettlement Action Plan (RAP) Trigger Event occurs. Moreover, BHP has committed to a 12-month lock-up of its Lifezone shares, and any post-lock-up divestitures must first be offered to Lifezone.

    Next Steps: Financing and Strategic Partnerships

    The acquisition marks a transformative milestone for Lifezone as it advances the Kabanga project toward FID. BHP’s exit comes as the project transitions into development, with Lifezone emphasizing value creation for all stakeholders, including Tanzania and local communities.

    Standard Chartered Bank has been appointed financial adviser, with near-term funding underway to support early construction and RAP activities. Simultaneously, Lifezone is engaged in talks with several major industrial partners for long-term strategic collaborations.

  • Pre-Market Momentum Builds For Helius Medical (HSDT) Stock

    Pre-Market Momentum Builds For Helius Medical (HSDT) Stock

    Shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) jumped 90.22% to $16.93 in pre-market trading following the company’s announcement of very positive Stroke Registrational Program (SRP) findings.

    Breakthrough Clinical Results from PoNS Therapy

    Helius Medical, operating under the FDA’s Breakthrough Device Designation, announced positive results from its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program.

    In stroke patients receiving active PoNS therapy, the program’s main double-blind randomized controlled study demonstrated a statistically significant improvement in gait and balance, meeting its primary aim. Even after integrating data from an open-label research using statistical techniques to balance baseline characteristics, these benefits persisted.

    Furthermore, the studies showed acceptable patient acceptability and reported few side effects, supporting the PoNS device’s safety profile.

    A Step Forward in Post-Stroke Care

    The SRP’s positive outcomes represent a significant advancement for Helius Medical in improving chronic stroke patients’ recovery. According to the business, the results might open up a new treatment option for the more than 7 million Americans who suffer from the long-term consequences of stroke, 80% of whom have severe impairments in their gait and balance.

    Later this quarter, Helius plans to submit these data to the FDA for consideration as part of an application for an indication in stroke rehabilitation

    Coordinated Multi-Trial Effort Supports FDA Submission

    The SRP was launched in March 2024 and consists of two sponsor-initiated pivotal trials: a single-arm study that began in April 2024 and a double-blind, randomized controlled trial. The findings are further supported by another investigator-led research that was started in late 2023 by Drs. Steve Kautz (MUSC) and Mark Bowden (Brooks Rehabilitation).

    All three trials were structured with consistent study designs and endpoints to measure improvements in gait and balance after 12 weeks of PoNS therapy.

    Path Ahead for Regulatory Review

    Under the existing Breakthrough Device Designation, Helius Medical intends to submit to the FDA in Q3 2025. The business is hopeful that these strong clinical findings will speed up regulatory approval and eventually offer significant comfort for stroke survivors, even if the PoNS device is not currently licensed in the United States for stroke-related rehabilitation.

  • Lucid (LCID) Shares Jump On Strategic Robotaxi Partnership

    Lucid (LCID) Shares Jump On Strategic Robotaxi Partnership

    Lucid Group, Inc. (NASDAQ: LCID) witnessed a substantial surge in its stock price, climbing 44.98% to trade at $3.32 as of the latest check. Following the company’s announcement of a next-generation premium global robotaxi project in partnership with Nuro, Inc. and Uber Technologies, Inc. (NYSE: UBER), LCID stock saw a dramatic increase in value.

    In late 2026, the program—which was created especially for the Uber ride-hailing ecosystem—will make its debut in a major American metropolis and promises a pleasant, scalable, and safe autonomous experience.

    Integration of Technology for Scalable Autonomy

    The robotaxi platform combines Uber’s vast ride-hailing network, Nuro’s Level 4 autonomous “Nuro Driver” technology, and Lucid’s (LCID) cutting-edge Gravity vehicle design. This three-pronged strategy combines advanced AI-powered autonomy, software-defined vehicle intelligence, and international ride-sharing logistics to create a system designed for large-scale urban transportation.

    The collaboration aims to deploy over 20,000 Lucid vehicles equipped with the Nuro Driver over the next six years. These vehicles will be operated directly by Uber or its authorized fleet partners and accessed exclusively through the Uber app.

    Prototype in Operation; Multi-Billion Dollar Investment Pipeline

    The initial prototype is already in autonomous operation at Nuro’s Las Vegas proving grounds, marking a major step toward real-world deployment. Uber, signaling deepened commitment, intends to make several hundred million dollars in strategic investments in both Lucid and Nuro to accelerate development and deployment.

    These investments also reinforce confidence in LCID’s zonal vehicle architecture, long-range capability, and premium, spacious interiors—all critical for an optimized autonomous ride-hailing experience.

    Enabling the Future of Autonomous Urban Transport

    This collaboration showcases the convergence of proven AV technology, premium vehicle platforms, and real-world scalability. Nuro brings nearly a decade of AI-first autonomous expertise, validated through extensive driverless deployments.

    Lucid’s Gravity platform will feature integrated AV hardware during assembly, and upon deployment, will receive Nuro’s AI-driven software. The result is a comprehensive robotaxi solution poised to serve millions globally, reshaping how cities experience urban transport and autonomous mobility.

  • Pre-Market Spike For Nuwellis After Securing New Blood Filtering Patent

    Pre-Market Spike For Nuwellis After Securing New Blood Filtering Patent

    The stock price of Nuwellis, Inc. (NASDAQ: NUWE) surged 156.71% to $17.70 during pre-market activity. The sharp rise in value, which marked a shift in the company’s technological and strategic orientation, was caused by a newly granted U.S. patent.

    Breakthrough Patent Strengthens Technological Edge

    On July 15, 2025, Nuwellis was officially issued U.S. Patent No. 12,357,734 by the U.S. Patent and Trademark Office. The patent, “Extracorporeal Blood Filtering Machine and Methods,” broadens the company’s intellectual property portfolio while resolving a chronic issue in continuous renal replacement therapy (CRRT).

    By taking into consideration differences in the density of replacement fluids and effluent—a frequently disregarded but clinically important variable—the patented approach increases the precision of fluid balance.

    A fluid density of 1 g/mL is the default for the majority of CRRT systems now in use. This simplicity can result in significant fluid imbalance mistakes. With Nuwellis’ invention, fluid density may be ascertained by derived metrics, machine measurements, or user input, allowing for more accurate volumetric flow tracking and better clinical results.

    Strategic IP Portfolio Expansion

    The inclusion of this patent is consistent with Nuwellis’ ongoing commitment to innovation. The company’s growing patent portfolio supports its mission to enhance extracorporeal fluid management and generate long-term, sustainable revenue.

    By addressing identified gaps in clinical technology, Nuwellis continues to hold its position as a pioneer in patient-centric treatment solutions. Every patent that the business has acquired not only protects its intellectual property but also greatly enhances its competitive edge and sets it apart in the marketplace.

    Strengthening of Leadership By Appointing a CEO

    In line with its strategic goals, Nuwellis recently announced the hiring of John Erb as CEO. Having held the role from 2015 to 2020 and as interim CEO since February 2025, Erb brings continuity, experience, and a new viewpoint to the role.

    The Board’s decision demonstrates its confidence in Erb’s capacity to steer the company toward future growth and operational efficiency. NUWE has already experienced a recovery in momentum and strategic clarity during his interim leadership.